A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Lee, Dong Ki; Park, Sook Ryun; Kim, Yeul Hong; Lee, Yun-Gyoo; Shin, Su-Jin; Ahn, Beung-Chul; Lee, Sung Sook; Lim, Sun Min; Kim, Hye Ryun; Cho, Byoung Chul; Hong, Min Hee

doi:10.1080/2162402x.2024.2371563

OncoImmunology

2024

DOI: 10.1080/2162402x.2024.2371563

|View full text |Cite

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Dong Ki Lee,

Sook Ryun Park,

Yeul Hong Kim

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Uddin,

Wang,

Yang

2024

Advanced Science

View full text Add to dashboard Cite

Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. Resistance to currently available anticancer drugs results in poor overall and disease‐free survival rates for cancer patients. There are multiple mechanisms through which tumor cells develop resistance to therapeutic agents. To date, efforts to overcome resistance have only achieved limited success. Epitranscriptomics, especially related to m6A RNA modification dysregulation in cancer, is an emerging mechanism for cancer therapy resistance. Here, recent studies regarding the contributions of m6A modification and its regulatory proteins to the development of resistance to different cancer therapies are comprehensively reviewed. The promise and potential limitations of targeting these entities to overcome resistance to various anticancer therapies are also discussed.

show abstract

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Uddin,

Wang,

Yang

2024

Advanced Science

View full text Add to dashboard Cite

show abstract

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Wang,

Ye,

et al. 2024

MedComm

View full text Add to dashboard Cite

Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its highest incidence and mortality rates reported in China. The complex molecular mechanisms underlying EC, coupled with the differential incidence of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) across various regions, highlight the necessity for in‐depth research targeting molecular pathogenesis and innovative treatment strategies. Despite recent progress in targeted therapy and immunotherapy, challenges such as drug resistance and the lack of effective biomarkers for patient selection persist, impeding the optimization of therapeutic outcomes. Our review delves into the molecular pathology of EC, emphasizing genetic and epigenetic alterations, aberrant signaling pathways, tumor microenvironment factors, and the mechanisms of metastasis and immune evasion. We further scrutinize the current landscape of targeted therapies, including the roles of EGFR, HER2, and VEGFR, alongside the transformative impact of ICIs. The discussion extends to evaluating combination therapies, spotlighting the synergy between targeted and immune‐mediated treatments, and introduces the burgeoning domain of antibody–drug conjugates, bispecific antibodies, and multitarget‐directed ligands. This review lies in its holistic synthesis of EC's molecular underpinnings and therapeutic interventions, fused with an outlook on future directions including overcoming resistance mechanisms, biomarker discovery, and the potential of novel drug formulations.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Cited by 2 publications

References 69 publications

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Contact Info

Product

Resources

About

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Cited by 2 publications

References 69 publications

Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Contact Info

Product

Resources

About

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities

Epitranscriptomic RNA m⁶A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities